WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

WuXi AppTec Co, Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hang Zhou, PhD, senior vice president and head of bioprocess research and development , WuXi Biologics. [WuXi Biologics] Raman spectroscopy has become a first-choice PAT for monitoring and ...

In March, WuXi AppTec split from the Biotechnology Innovation Organisation (BIO) after the trade organisation voiced its support for the legislation. The Act’s backers - Representatives Raja ...

including sister company WuXi AppTec, on national security grounds. It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now ...